{"entity":{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","aka":["Vironexis Biotherapeutics Inc."],"tldr":"Vironexis Biotherapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the AAV-delivered T-cell engager gene therapies VNX-101 and VNX-202 in acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma and advanced solid tumours.","summary":"Vironexis Biotherapeutics is a clinical-stage biotechnology company developing AAV-delivered, in vivo T-cell engager gene therapies on its TransJoin platform, given as a single intravenous dose. Its lead programme VNX-101 is in phase 1/2 for CD19-positive leukaemias and lymphomas, with VNX-202 for HER2-positive cancers. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06533579 (phase 1/2, Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)) and NCT07192432 (phase 1/2, Gene Therapy for HER-Positive Cancer (SENTRY-HER2)). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://vironexis.com"},{"label":"ClinicalTrials.gov: trials led by Vironexis Biotherapeutics","url":"https://clinicaltrials.gov/search?lead=Vironexis%20Biotherapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["all-leukemia","dlbcl","cll","non-hodgkin-lymphoma","follicular-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06533579","nct07192432"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"San Diego, California","country":"US","companyType":"biotech","website":"https://vironexis.com","founded":2021,"stage":"startup","investors":[],"funding":[]},"route":"/companies/vironexis-biotherapeutics/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"trial":[{"id":"nct06533579","kind":"trial","name":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","route":"/trials/nct06533579/"},{"id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","route":"/trials/nct07192432/"}]}}